ММВБ 4 236 -0,5%  Nasdaq 15 236 0,1%  Биткойн 60 618 0,4%  USD/RUB 69,4796 0,0% 
РТС 1 916 -0,2%  S&P500 4 575 -0,2%  Нефть 86,1 -0,1%  EUR/RUB 80,6010 0,0% 
Dow 35 757 0,0%  FTSE100 7 278 0,8%  Золото 1 787 -0,3%  EUR/USD 1,1601 0,0% 

Peplin Inc Chess Depository Interests repr 1/20 Shs - Профиль

Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus. On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.




Добавить или редактировать инструмент